|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2000-6-21
|
|
pubmed:abstractText |
Administration of bovine type II collagen (CII) or of its peptide either orally or nasally has been reported to suppress the development of collagen induced arthritis (CIA) in mice and rats. We examined the inhibitory effects of CII delivered by each route on CIA in DBA/1J mice to determine which route was superior.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1038-44
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10782834-Administration, Intranasal,
pubmed-meshheading:10782834-Administration, Oral,
pubmed-meshheading:10782834-Animals,
pubmed-meshheading:10782834-Arthritis,
pubmed-meshheading:10782834-Cattle,
pubmed-meshheading:10782834-Collagen,
pubmed-meshheading:10782834-Disease Models, Animal,
pubmed-meshheading:10782834-Dose-Response Relationship, Drug,
pubmed-meshheading:10782834-Immunoglobulin G,
pubmed-meshheading:10782834-Male,
pubmed-meshheading:10782834-Mice,
pubmed-meshheading:10782834-Mice, Inbred DBA,
pubmed-meshheading:10782834-Nasal Mucosa,
pubmed-meshheading:10782834-T-Lymphocytes
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis.
|
|
pubmed:affiliation |
Department of Microbiology, The Immunobiology Vaccine Center, University of Alabama at Birmingham, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
